Targeting the nuclear transport machinery by rational drug design

Current Pharmaceutical Design

Volumn 19, Issue 12, 2013, Pages 2318-2325

  Mao, Lei ^a   Yang, Yongliang ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

CRM1 inhibitors; Molecular simulation; Nuclear protein transport; Rational drug design

Indexed keywords

5,6 DEHYDROVALTRATE; ANGUINOMYCIN C; ANGUINOMYCIN D; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BETA CATENIN; CBS 9106; CSB 9106; EXPORTIN 1; GONIOTHALAMIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTOMYCIN B; PFK 050 637; PFK 050 638; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; RATJADONE; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; VALTRATE; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CYTOTOXICITY; DRUG DESIGN; HUMAN IMMUNODEFICIENCY VIRUS; MICHAEL ADDITION; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN CONFORMATION; PROTEIN EXPRESSION; SIMULATION; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; CELL NUCLEUS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; KARYOPHERINS; KINETICS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84877791472     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319120018     Document Type: Article

References (49)

1. Fahrenkrog, B. and U. Aebi. The nuclear pore complex: nucleocytoplasmic transport and beyond. Nat Rev Mol Cell Biol 2003; 4: 757-66.
2. Cook A, Bono F, Jinek M, Conti E. Structural biology of nucleocytoplasmic transport. Annu Rev Biochem 2007; 76: 647-71.
3. Kalderon D, Richardson WD, Markham AF, Smith AE. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature 1984; 311: 33-8.
4. Lee BJ, Cansizoglu AE, Süel KE, Louis TH, Zhang Z, Chook YM. Rules for nuclear localization sequence recognition by karyopherin beta 2. Cell 2006; 126: 543-58.
5. Fischer U, Huber J, Boelens WC, Mattaj IW, Lührmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 1995; 82: 475-83.
6. Wen W, Meinkoth JL, Tsien RY, Taylor SS. Identification of a Signal for Rapid Export of Proteins from the Nucleus. Cell 1995; 82: 463-73.
7. Görlich D, Panté N, Kutay U, Aebi U, Bischoff FR. Identification of different roles for RanGDP and RanGTP in nuclear protein import. EMBO J 1996; 15: 5584-94.
8. Dasso M. The Ran GTPase: theme and variations. Curr Biol 2002; 12: 502-8.
9. Weis, K. Regulating access to the genome: Nucleocytoplasmic transport throughout the cell cycle. Cell 2003; 112: 441-51.
10. Güttler T, Görlich D. Ran-dependent nuclear export mediators: a structural perspective. EMBO J 2011; 30: 3457-74.
11. Kutay U, Bischoff FR, Kostka S, Kraft R, Görlich D. Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor. Cell 1997; 90: 1061-71.
12. Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 2007; 17: 193-201.
13. Kudo N, Wolff B, Sekimoto T, et al. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 1998; 242: 540-7.
14. Henderson BR, Eleftheriou A. A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. Exp Cell Res 2000; 256: p. 213-24.
15. la Cour T, Kiemer L, Mølgaard A, Gupta R, Skriver K, Brunak S. Analysis and prediction of leucine-rich nuclear export signals. Protein Eng Des Sel 2004; 17: 527-36.
16. Kalland KH, Szilvay AM, Brokstad KA, Saetrevik W, Haukenes G. The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasm and nuclear compartments. Mol Cell Biol 1994; 14: 7436-44.
17. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997; 90: 1051-60.
18. Fukuda M, Asano S, Nakamura T, et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997; 390: 308-11.
19. Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997; 90: 1041-50.
20. Yashiroda Y, Yoshida M. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem 2003; 10: 741-8.
21. Rodriguez MS, Thompson J, Hay RT, Dargemont C. Nuclear retention of IkappaBalpha protects it from signal-induced degradation and inhibits nuclear factor kappaB transcriptional activation. J Biol Chem 1999. 274(13): 9108-15.
22. Taagepera S, McDonald D, Loeb JE, et al. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci USA 1998; 95: 7457-62.
23. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228-34.
24. Arnaoutov A, Azuma Y, Ribbeck K, et al. Crm1 is a mitotic effector of Ran-GTP in somatic cells. Nat Cell Biol 2005; 7: 626-32.
25. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005; 7: 823-30.
26. Monecke T, Güttler T, Neumann P, Dickmanns A, Görlich D, Ficner R. Crystal Structure of the Nuclear Export Receptor CRM1 in Complex with Snurportin1 and RanGTP. Science 2009; 324: 1087-91.
27. Dong X, Biswas A, Süel KE, et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009; 458: 1136-41.
28. Hamamoto T, Seto H, Beppu T. Leptomycins A and B, new antifungal antibiotics. II. Structure elucidation. J Antibiot (Tokyo) 1983; 36: 646-50.
29. Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, Beppu T. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J Biol Chem 1994; 269: 6320-4.
30. Picman AK, Rodriguez E, Towers GH. Formation of adducts of parthenin and related sesquiterpene lactones with cysteine and glutathione. Chem Biol Interact 1979; 28: 83-9.
31. Kudo N, Matsumori N, Taoka H, et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999; 96: 9112-7.
32. Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol 1986; 16: 95-101.
33. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer 1996; 74: 648-9.
34. Mutka SC, Yang WQ, Dong SD, et al. Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo. Cancer Res 2009; 69: 510-7.
35. Daelemans D, Afonina E, Nilsson J, et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci USA 2002; 99: 14440-5.
36. Murakami N, Ye Y, Kawanishi M, et al. New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg Med Chem Lett 2002; 12: 2807-10.
37. Tamura S, Shimizu N, Fujiwara K, Kaneko M, Kimura T, Murakami N. Bioisostere of valtrate, anti-HIV principle by inhibition for nuclear export of Rev. Bioorg Med Chem Lett 2010; 20: 2159-62.
38. Kau TR, Schroeder F, Ramaswamy S, et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003; 4: 463-76.
39. Köster M, Lykke-Andersen S, Elnakady YA, et al. Ratjadones inhibit nuclear export by blocking CRM1/exportin 1. Exp Cell Res 2003; 286: 321-31.
40. Meissner T, Krause E, Vinkemeier U. Vinkemeier, Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett 2004; 576: 27-30.
41. Monovich L, Koch KA, Burgis R, et al. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. Biochim Biophys Acta 2009; 1789: 422-31.
42. Bonazzi S, Eidam O, Güttinger S, et al. Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport. J Am Chem Soc 2010; 132: 1432-42.
43. Hilliard M, Frohnert C, Spillner C, et al. The anti-inflammatory prostaglandin 15-deoxy-delta(12,14)-PGJ(2) Inhibits CRM1-dependent nuclear protein export. J Biol Chem 2010; 285: 22202-10.
44. Wach JY, Güttinger S, Kutay U, Gademann K. The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg Med Chem Lett 2010; 20: 2843-6.
45. Sakakibara K, Saito N, Sato T, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood, 2011. 118: 3922-31.
46. Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005; 26: 1781-802.
47. Aloisi A, Di Gregorio S, Stagno F, et al. BCR-ABL nuclear entrapment kills human CMIL cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood 2006; 107: 1591-8.
48. Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012; 120(9): 1765-73.
49. Faustino RS, Nelson TJ, Terzic A, Perez-Terzic C. Nuclear transport: target for therapy. Clin Pharmacol Ther 2007; 81: 880-6.